Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?
BMC Cancer, July 2011
André Albergaria, Sara Ricardo, Fernanda Milanezi, Vítor Carneiro, Isabel Amendoeira, Daniella Vieira, Jorge Cameselle-Teijeiro, Fernando Schmitt
A breast cancer prognostic tool should ideally be applicable to all types of invasive breast lesions. A number of studies have shown histopathological grade to be an independent prognostic factor in breast cancer, adding prognostic power to nodal stage and tumour size. The Nottingham Prognostic Index has been shown to accurately predict patient outcome in stratified groups with a follow-up period of 15 years after primary diagnosis of breast cancer. Clinically, breast tumours that lack the expression of Oestrogen Receptor, Progesterone Receptor and Human Epidermal growth factor Receptor 2 (HER2) are identified as presenting a "triple-negative" phenotype or as triple-negative breast cancers. These poor outcome tumours represent an easily recognisable prognostic group of breast cancer with aggressive behaviour that currently lack the benefit of available systemic therapy. There are conflicting results on the prevalence of lymph node metastasis at the time of diagnosis in triple-negative breast cancer patients but it is currently accepted that triple-negative breast cancer does not metastasize to axillary nodes and bones as frequently as the non-triple-negative carcinomas, favouring instead, a preferentially haematogenous spread. Hypothetically, this particular tumour dissemination pattern would impair the reliability of using Nottingham Prognostic Index as a tool for triple-negative breast cancer prognostication.
|Members of the public||2||100%|
|Readers by professional status||Count||As %|
|Student > Ph. D. Student||7||18%|
|Student > Postgraduate||5||13%|
|Student > Master||4||10%|
|Student > Bachelor||4||10%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||18||46%|
|Agricultural and Biological Sciences||7||18%|
|Biochemistry, Genetics and Molecular Biology||2||5%|
|Pharmacology, Toxicology and Pharmaceutical Science||2||5%|